147 related articles for article (PubMed ID: 34926722)
21. Quantitation of hepatitis C virus RNA in peripheral blood mononuclear cells in HCV-monoinfection and HIV/HCV-coinfection.
Chary A; Winters MA; Eisen R; Knight TH; Asmuth DM; Holodniy M
J Med Virol; 2012 Mar; 84(3):431-7. PubMed ID: 22246828
[TBL] [Abstract][Full Text] [Related]
22. Disparities in Treatment with Direct-Acting Hepatitis C Virus Antivirals Persist Among Adults Coinfected with HIV and Hepatitis C Virus in US Clinics, 2010-2018.
Simoncini GM; Hou Q; Carlson K; Buchacz K; Tedaldi E; Palella F; Durham M; Li J;
AIDS Patient Care STDS; 2021 Oct; 35(10):392-400. PubMed ID: 34623891
[TBL] [Abstract][Full Text] [Related]
23. Modeling hepatitis C virus therapies combining drugs and lectin affinity plasmapheresis.
Tullis RH; Duffin RP; Ichim TE; Joyce JA; Levin NW
Blood Purif; 2010; 29(2):210-5. PubMed ID: 20093829
[TBL] [Abstract][Full Text] [Related]
24. Kidney and liver organ transplantation in persons with human immunodeficiency virus: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(4):1-56. PubMed ID: 23074407
[TBL] [Abstract][Full Text] [Related]
25. Hepatitis C Virus Prevalence in Egyptian Americans in Southern California.
Saab S; Viramontes MR; Chalifoux SL; Craw CJ; Ramirez SD; Bau SN; Arevalo DG; Saab EG; Saab CE; Craw CS; Estafanous A; Messiah R; Messiah W; El Kabany M
J Clin Gastroenterol; 2018 Jan; 52(1):55-59. PubMed ID: 28617761
[TBL] [Abstract][Full Text] [Related]
26. Hepatitis C viral load, genotype, and increased risk of developing end-stage renal disease: REVEAL-HCV study.
Lai TS; Lee MH; Yang HI; You SL; Lu SN; Wang LY; Yuan Y; L'Italien G; Chien KL; Chen CJ;
Hepatology; 2017 Sep; 66(3):784-793. PubMed ID: 28370058
[TBL] [Abstract][Full Text] [Related]
27. Impact of hepatitis C virus point-of-care RNA viral load testing compared with laboratory-based testing on uptake of RNA testing and treatment, and turnaround times: a systematic review and meta-analysis.
Trickey A; Fajardo E; Alemu D; Artenie AA; Easterbrook P
Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):253-270. PubMed ID: 36706775
[TBL] [Abstract][Full Text] [Related]
28. Impact of hepatitis C virus and insurance coverage on mortality.
Bush H; Paik J; Golabi P; de Avila L; Escheik C; Younossi ZM
Am J Manag Care; 2019 Feb; 25(2):61-67. PubMed ID: 30763036
[TBL] [Abstract][Full Text] [Related]
29. Optimizing hepatitis C therapy in HIV/hepatitis C virus (HCV) coinfected patients: Analysis of HCV viral kinetics on treatment.
James PD; Wong DKh
Can J Infect Dis Med Microbiol; 2012; 23(1):31-5. PubMed ID: 23450124
[TBL] [Abstract][Full Text] [Related]
30. Implications of HCV RNA level at week 4 of direct antiviral treatments for hepatitis C.
Johnson K; Green PK; Ioannou GN
J Viral Hepat; 2017 Nov; 24(11):966-975. PubMed ID: 28585416
[TBL] [Abstract][Full Text] [Related]
31. NIH Consensus Statement on Management of Hepatitis C: 2002.
NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
[TBL] [Abstract][Full Text] [Related]
32. Sustained virological response is associated with clearance of hepatitis C virus RNA and a decrease in hepatitis C virus antibody.
Maylin S; Martinot-Peignoux M; Ripault MP; Moucari R; Cardoso AC; Boyer N; Giuily N; Castelnau C; Pouteau M; Asselah T; Nicolas-Chanoine MH; Marcellin P
Liver Int; 2009 Apr; 29(4):511-7. PubMed ID: 19076273
[TBL] [Abstract][Full Text] [Related]
33. Confluence of Epidemics of Hepatitis C, Diabetes, Obesity, and Chronic Kidney Disease in the United States Population.
Lazo M; Nwankwo C; Daya NR; Thomas DL; Mehta SH; Juraschek S; Willis K; Selvin E
Clin Gastroenterol Hepatol; 2017 Dec; 15(12):1957-1964.e7. PubMed ID: 28579183
[TBL] [Abstract][Full Text] [Related]
34. Impact of chronic hepatitis C on HIV-1 disease progression.
Carlos Martín J; Castilla J; López M; Arranz R; González-Lahoz J; Soriano V
HIV Clin Trials; 2004; 5(3):125-31. PubMed ID: 15248136
[TBL] [Abstract][Full Text] [Related]
35. Spontaneous Viral Load Decline and Subsequent Clearance of Chronic Hepatitis C Virus in Postpartum Women Correlates With Favorable Interleukin-28B Gene Allele.
Hashem M; Jhaveri R; Saleh DA; Sharaf SA; El-Mougy F; Abdelsalam L; Shardell MD; El-Ghazaly H; El-Kamary SS
Clin Infect Dis; 2017 Sep; 65(6):999-1005. PubMed ID: 28903504
[TBL] [Abstract][Full Text] [Related]
36. Treatment of hepatitis C virus infection with human ezrin peptide one (HEP1) in HIV infected patients.
Salamov G; Holms R; Bessler WG; Ataullakhanov R
Arzneimittelforschung; 2007; 57(7):497-504. PubMed ID: 17803064
[TBL] [Abstract][Full Text] [Related]
37. Association of lipid profiles with hepatitis C viral load in chronic hepatitis C patients with genotype 1 or 2 infection.
Hsu CS; Liu CH; Liu CJ; Wang CC; Chen CL; Lai MY; Chen PJ; Chen DS; Kao JH
Am J Gastroenterol; 2009 Mar; 104(3):598-604. PubMed ID: 19262519
[TBL] [Abstract][Full Text] [Related]
38. Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor.
Mocroft A; Gill MJ; Davidson W; Phillips AN
AIDS; 1998 Nov; 12(16):2161-7. PubMed ID: 9833857
[TBL] [Abstract][Full Text] [Related]
39. Rapid virological response assessment by Abbott RealTime hepatitis C virus assay for predicting sustained virological responses in patients with hepatitis C virus genotype 1 treated with pegylated-interferon and ribavirin.
Su PY; Yen HH; Hsu YC; Wu SS; Kor CT; Su WW
Kaohsiung J Med Sci; 2016 Jul; 32(7):381-6. PubMed ID: 27450028
[TBL] [Abstract][Full Text] [Related]
40. Clinical characteristics of patients with chronic hepatitis C showing biochemical remission, without hepatitis C virus eradication, as a result of interferon therapy. The Osaka Liver Disease Study Group.
Kasahara A; Hayashi N; Mochizuki K; Hiramatsu N; Sasaki Y; Kakumu S; Kiyosawa K; Okita K
J Viral Hepat; 2000 Sep; 7(5):343-51. PubMed ID: 10971822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
